UCB Inspired by patients. Driven by science.€¦ · UCB Inspired by patients. Driven by science. 2017 full year financial report Brussels, 22 February 2018. Disclaimer and safe harbor

UCB Inspired by patients.Driven by science.

2017 full year financial report

Brussels, 22 February 2018

2017 FY resultsDisclaimer and safe harbor 2

Forward-looking statementsThis presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”,“expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward-looking statements are basedon current plans, estimates and beliefs of management. By their nature, such forward-looking statements are not guarantees of future performanceand are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance orachievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied bysuch forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitiveconditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research anddevelopment, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmentalinvestigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchangerate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. There is noguarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developedand approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject todifferences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they aremarketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and thereimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-lookingstatements are made only as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statementsin this presentation to reflect any change in its expectations with regard thereto or any change in events, conditions, for circumstances on which anysuch statement is based, unless such statement is required pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

2017 FY results 3UCB FY 2017 information flow

ן A strong year 2017, reinforcing a solid foundation for investing in future growth• Jean-Christophe Tellier, CEO

ן Increasing value of UCB's early and late-stage pipeline• Dhavalkumar Patel, CSO

ן Bimekizumab Phase 2b: 3 x positive results• Dominique Baeten, Head of the New Patient Value Mission

ן Continued above market growth in 2017• Detlef Thielgen, CFO

ן Conclusion• Jean-Christophe Tellier, CEO

ן Q&A

2017 FY resultsDriving value for patients 4

Examples for 2017 achievements

From Patient to Science• Cimzia® for women of childbearing age• UCB0107 – Tau antibody

From Science to Solution• bimekizumab: specific antibody targeting both IL-17A and IL-17F• padsevonil: high drug-resistant epilepsy

From Solution to Patient• Innovative extrapolation - faster access

for patientsBriviact® monotherapy, Vimpat® pediatric epilepsy

• Algorithm defined with Georgia Tech to predict the best next treatment for epilepsy patients

2017 FY resultsUCB is progressing on our strategic growth path 5

1 CRL: complete response letter2 NME: New Molecular Entity3 OTC: over the counter

Grow core productsCimzia®, Vimpat®, Keppra®, Briviact® + Neupro®

combined net sales: € 3.6 billion (+13%)

Advance and prepare launch of next wavebimekizumab with strong positive & competitive Phase 2b resultsEVENITY™ ARCH topline results + CRL1 in the U.S., filed in the EU

Deliver breakthrough solutionsTranslating scientific hypotheses into clinical developmentClinical pipeline with 12 NMEs2

Continued focusOut-licensing of Xyzal® as OTC3 treatment in allergyAcquisition of Beryllium, LLC.

Stronggrowth

Growth expansion

Breakthrough phase

Increased 2017 financial outlook met30% recurring EBITDA / revenue ratio achieved

2017 achievements – delivering on our commitments

*The trademark EVENITY™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). EVENITY™ (romosozumab) is developed in partnership with Amgen globally.

Increasing value of UCB's early and late-stage pipeline

Dhavalkumar Patel, MD, PhDCSO

6

2017 FY resultsIncreasing value of UCB's early and late-stage pipeline 7

Driven by strong UCB science and technology platforms

Filing

bimekizumabpsoriasis, psoriatic arthritis and ankylosing spondylitis

dapirolizumab pegolLupus

padsevonilepilepsyseletalisib

rozanolixizumabimmune thrombocytopenia

UCB7858

radiprodil

UCB6673

UCB4144

UCB0599 Phase 3

Phase 1

UCB0159

Phase 2

romosozumabosteoporosis

UCB0107

2017 FY results

Key insight

We keep strengthening our leadership in epilepsy with padsevonil

8

Source: Brodie & Kwan (2002), Staged approach to epilepsy management. Neurology 58(Suppl 5):S2-S81: patients who failed four anti-epileptic drugs and have at least four seizures/week

… is driven by a unique dual mechanism… is driven by a unique dual mechanism

Key facts

•~30% of epilepsy patients are drug-resistant and lack treatment options

•Padsevonil showed positive results in study aimed at highly drug-resistant epilepsy patients1

•Padsevonil has a remarkable synergy between two clinical anti-seizure mechanisms (SV2A & GABA-A)

Padsevonil’s unique impact…Padsevonil’s unique impact…

Pre- & Post-Synaptic Inhibition (PPSI)

2017 FY results

UCB0107, an anti-Tau antibody forProgressive Supranuclear Palsy & Alzheimer’s disease

9

Source: UCB internal dataAD: Alzheimer’s diseasePSP: Progressive Nuclear Palsy

•PSP is a rare, rapidly progressing tauopathy with debilitating cognitive & motor symptoms

•Alzheimer’s Disease is also a tauopathy, with high prevalence and economic impact

•Tau misfolding and aggregation leads to neuronal death and disease spread

UCB0107 blocks tau uptake and aggregation

UCB0107 blocks tau uptake and aggregation

Key facts Key insights

Tau seeds spread from dying cells to

infect other neurons

UCB0107 was generated to block spreading of tau

seeds from patient materials

AD

PSP

Tau seed

2017 FY results

Rozanolixizumab, a first-in-class SubQ treatment for IgG-mediated diseases like ITP & Myasthenia Gravis

10

Source: Kiessling et al. STM 2017Note: SubQ, sub-cutaneous; PEX, plasma exchange; FcRn, neonatal Fc receptor; IgG, immunoglobulin; Immune thrombocytopenia (ITP); Myasthenia gravis (MG); Chronic inflammatory demyelinating polyneuropathy (CIDP)

Key facts

• Pathogenic IgG autoantibodies are key in multiple debilitating IgG autoantibody-mediated diseases like immune thrombocytopenia (ITP), myasthenia gravis (MG) and chronic inflammatory demyelinating polyneuropathy (CIDP)

• Rozanolixizumab blocks FcRn-IgG interactions so inhibiting IgG recycling & inducing removal of pathogenic IgG autoantibodies

• Novel approach should allow patients to live a more independent life

Rozanolixizumab is set to replace standard IVIg and PEX therapies

Rozanolixizumab is set to replace standard IVIg and PEX therapies

Key data

Data indicate dose-dependentlowering of IgG serum levels in healthy volunteers

Data indicate dose-dependentlowering of IgG serum levels in healthy volunteers

Rel

ativ

e ch

ange

from

bas

elin

e (%

) –se

rum

Ig

G c

once

ntra

tion

in h

ealth

y su

bjec

ts

Relative study day

Rozanolixizumab achieved proof of concept in ITP, recruitment for higher doses is ongoing

2017 FY results

Our antibody technology platform is a core value driver of our pipeline

11

Key facts

• Highly automated and efficient discovery process

• Proprietary transient and stable mammalian expression platforms

• Range of different formats including Fab and bispecific antibody

Strong antibody platform Strong antibody platform • UCB0159 has good potency for multiple cytokines(IL17 dimers, TNF) & Albumin

• Targeting both TNF and IL17A/F pathways, may reduce biological redundancy through greater/synergistic inflammation suppression

UCB0159 is our first bispecific antibody in the clinic, more to follow

UCB0159 is our first bispecific antibody in the clinic, more to follow

Key example

IL17-A/IL17-A homodimer

IL17-F/IL17-F homodimer

IL17-A/IL17-F heterodimer

Albumin TNF

12

Bimekizumab Phase 2b:3 x positive results

Dominique Baeten, MD, PhDProfessor of RheumatologyHead of the New Patient Value Mission

2017 FY results

Translating scientific hypotheses into clinical differentiation13

Dual blockade of IL-17F and IL-17A by bimekizumab

Dual blockade of IL-17F on top of IL-17A

will improve therapeutic efficacy versus targeting IL-17A alone

IL-17F

IL-17RAIL-17RC

IL-17A

Bimekizumab specifically and completely blocks IL-17F and IL-17A

IL-17F and IL-17A are twin cytokines

driving joint and skin inflammation

2017 FY resultsTranslating scientific hypotheses into clinical differentiation 14

Bimekizumab proof of concept

Glatt et al, Annals of the Rheumatic Diseases 2018

Depth of response to bimekizumabversus anti-IL-17A

in multiple in vitro assays

Bimekizumab inducedrapid and profound joint and skin responses

in psoriatic arthritis

7%15%

40%57%

Week 8 Week 20

Placebo Bimekizumab

ACR

50 (%

)1% 1%

87% 93%

Week 8 Week 20

Placebo Bimekizumab

PASI

90

(%)

Time after administration Time after administration

0

100000

200000

300000

400000

500000

600000

700000

55%

(G)

Neu

troph

ilnu

mbe

r

1:10 Th17 supernatant

ACR50 - JointACR50 - Joint PASI90 - SkinPASI90 - SkinMigration of neutrophilsMigration of neutrophils

2017 FY results

• 250 patients living with chronic plaque psoriasis1

• 48 weeks

• placebo

• PASI90* response@ week 12

Psoriasis(NCT02905006)

Phase 2b results July 2017

Bimekizumab current development program 15

First monoclonal antibody neutralizing IL-17F on top of IL-17A

1 moderate to severe chonic plaque psoriasis* Defined as a patient who achieves 90% reduction from baseline in the PASI scoreSource: www.clinicaltrial.gov

Duration

Comparator

Endpoint

Results

• 303 patients living with ankylosing spondylitis

• 48 weeks

• placebo

• ASAS40 response @ week 12

Ankylosing spondylitis(NCT02963506)

Phase 2b results Dec 2017

• 206 patients living with active psoriatic arthritis

• 48 weeks

• placebo

• ACR50 response @ week 12

Psoriatic arthritis(NCT02969525)

Phase 2b results Dec 2017

All 3 studies in mixed population of anti-TNF-naïve and anti-TNF-incomplete responder patients

2017 FY resultsBimekizumab: Strong positive results from BE ACTIVE 16

Significantly improve joint and skin symptoms in phase 2b

ACR50: patients experiencing at least 50% improvement in joint symptoms

206 patients living with active psoriatic arthritis:Up to 46% achieved ACR501 with bimekizumab vs. 7% placebo

placebo12 weeks

bimekizumab12 weeks

2017 FY resultsBimekizumab: Strong positive results from BE ACTIVE 17

Significantly improve joint and skin symptoms in phase 2b

PASI90: patients experiencing at least 90% skin clearance

… and up to 65% of patients with bimekizumab achieved at least 90% skin clearance (PASI90) vs. 7% placebo

placebo12 weeks

bimekizumab12 weeks

2017 FY results

303 patients living with active ankylosing spondylitis:Up to 47% achieved ASAS401 with bimekizumab vs. 13% placebo

ASAS40: at least 40% improvement in symptoms, such as pain, physical function, and inflammation

Bimekizumab: Strong positive results from BE AGILE 18

Significant improvement in multiple dose groups in phase 2b

placebo12 weeks

bimekizumab12 weeks

2017 FY resultsBimekizumab: Strong positive results from BE ABLE 19

Significantly improve skin symptoms in phase 2b

1 Affected body surface area of at least 10% and PASI of at least 12PASI90: patients experiencing at least 90% skin clearance

250 patients living with moderate to severe chronic plaque psoriasis1:Up to 79% achieved at least 90% skin clearance (PASI90) with bimekizumab vs. 0% placebo

placebo12 weeks

bimekizumab12 weeks

2017 FY resultsBimekizumab: Strong positive results from BE ABLE 20

Significantly improve skin symptoms in phase 2b

1 Affected body surface area of at least 10% and PASI of at least 12PASI90: patients experiencing at least 90% skin clearance

250 patients living with moderate to severe chronic plaque psoriasis1:Up to 60% achieved complete skin clearance (PASI100) with bimekizumab vs. 0% placebo

placebo12 weeks

bimekizumab12 weeks

2017 FY resultsNext: Phase 3 programs for clinical differentiation 21

Robust Phase 2b studies in 3 related indications

• All 3 studies met primary and secondary endpoints

• Rapid and profound clinical efficacy on relevant endpoints

• Both for joints and for skin

• Consistent across the three 12-week, mixed population, Phase 2b studies

• With a favorable safety profile

Data support initiation of Phase 3 program

for clinical differentiation in all 3 indications

22

Continued above market growth in 2017

Detlef Thielgen, CFO

2017 FY resultsUCB FY 2017 financial highlights 23

Core product growth drive top and bottom line

CER: constant exchange rateOne-time other revenue of € 56 million for out-licensing the OTC-allergy drug Xyzal® (levoceterizine)

CER

+11%

+34%+33%

Actual

Revenue• Net sales up by 9% (+11% CER) to € 4.2 billion

driven by core products (€ 3.6 billion; +13%)

€ 4 530 million

Total operating expenses • Overall operating expense ratio improved to 48%• R&D expense +4%

€ 2 200 million

Recurring EBITDA • Higher gross profit • Improved operating expenses ratio

€ 1 375 million

Profit of the Group• € 753 million attributable to UCB shareholders (+45%)

€ 771 million

Core earnings per share Based on 188 million weighted average shares outstanding (2016: 188 million)

€ 4.82

+9%

+42%

+51% +52%

+2% +4%

+43%

2017 FY resultsStrong net sales growth from core products 24

Generating € 3.6 billion (+13%)

CER = constant currency exchange rates* Excluding € 28 million from hedging ** adjusted for venlafaxine ER divestiture (net sales of €89m in 2016)

Cimzia® € 1.42 bn +9% (+11% CER)• Sustainable performance

Vimpat® € 0.98 bn +19% (+21% CER)• Strong, sustainable growth in all markets

Keppra® € 0.78 bn +8% (+11% CER)• Strong growth in international markets, especially in Japan

Briviact® € 87 million > +100%• Launched in EU countries and North America

Neupro® € 314 million +5% (+7% CER)• Sustainable growth in all geographies

Established brands -16% (-15% CER)• High value divestitures to increase focus and enhance strategic flexibility – adjusted** -3%

2017 FY net sales*€ 4 154 million

2017 FY results 2530% rEBITDA target for 2018 - already reached in 2017Top line growth, efficient resources allocation and tight cost control lead to improved ratios*

69% 69% 70% 71%74%

2013 2014 2015 2016 2017

60% 57% 55% 52%48%

2013 2014 2015 2016 2017

* vs. revenue

Gross margin / revenue Operating expense / revenue

17% 18%21%

24.9%

30.3%

2013 2014 2015 2016 2017

Recurring EBITDA / revenue

30% target for 2018

2017 FY resultsSolid, sustainable top and bottom line growth 26

Strong foundation enabling future growth and investment in innovation

3.14 3.34 3.88

4.15 4.53

2013 2014 2015 2016 2017

€ bi

llion

0.54 0.61

0.82

1.03

1.38

2013 2014 2015 2016 2017€

billio

n

Recurring EBITDARevenue

2017 FY results2017 financial targets achieved 27

30.3 % rEBITDA margin – one year ahead of guidance

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge* Based on 188 million shares

Revenue € 4.4 - 4.5 billion € 4.53 billion (+9%)

rEBITDA € 1.25 – 1.35 billion€ 1.38 billion (+33%)

Core EPS* € 4.10 – 4.50€ 4.82 (+51%)

Net debt / rEBITDA = 1:1 by 20180.8 in 2016; 0.4 in 2017

rEBITDA / revenue ratio 30% in 201830.3% in 2017

'CVN' net sales ≥ € 3.1 billion by 2020€ 2.7 billion in 2017 (+12%)

Briviact® net sales ≥ € 450 million by 2026€ 87 million (+>100%) in 2017

2017 financial targets vs. 2017 achievements

Mid-term financial targets vs. 2017 achievements

2017 FY results

2018 financial targets

2018 financial outlook and new midterm guidance 28

Maximize (new) growth drivers and strengthen sustainability

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge* ~188 million shares weighted average outstanding

Revenue € 4.5 - 4.6 billion• Continued strong core product growth• One-time effects in 2017• Weak US$

rEBITDA € 1.3 – 1.4 billion• R&D expense ratio of ~26% (+/-1% point)• Launch preparations

Core EPS* € 4.30 – 4.70• Expected underlying tax ratio

in the "low twenties"

Guidance target 2021 and beyond

rEBITDA / revenue ratio of 31% in 2021UCB investing into the pipeline complemented with inorganic growth opportunities

Updated peak sales guidanceBriviact® > € 600 million in 2026

2017 FY resultsUCB's Patient Value Strategy 29

Our ambition is to be the patient preferred biotech leader, creating

patient value for specific populations through unique outcomes, the best experience and improving as many

of these lives as possible.

This will lead to sustainable growthfor UCB and its shareholders.

Value for patients

Mariana, living with epilepsy

Value for shareholders

2017 FY results

UCB's strategic growth pathTrue differentiation drives leadershipand sustainability

Your Questions, please

Strong growth

Growth expansion

Breakthroughphase

30

Further factsand figures

31

2017 FY resultsRecurring EBITDA 32

Solid growth - Improved operating expenses ratio

Restated after reclassification due to IFRS 15 EBIT: Earnings before interest and taxesCER: constant exchange rate EBITDA: Earning before interests, taxes, depreciation and amortization charges

2017 FY results2017 profit 33

CER: constant exchange rateEBIT: Earnings before interest and taxes

2017 FY resultsCore earnings per share 34

Strong growth of core net profit

2017 FY results

Numbers may not add due to roundingCER: constant exchange rate

2017 key product net sales performance 35

2017 FY resultsStrong Cash Flows 36

"Net debt/rEBITDA ratio of 1:1" achieved ahead of time in 2016

CAGR: composite annual growth rate

Cash flow from continuing operations Net debt & recurring EBITDA ratio

€ m

illion

267

537

204

726

896

2013 2014 2015 2016 2017

3.06*

2.13*

* KU rEBITDA prior to KU divestment added back

KremersUrban

divestiture

nitrates, venlafaxine ER

divestiture

2017 FY results 37Strong Cimzia® performance across all regions

1 2016 figures have been restated reflecting IFRS 15 implementation in 2017 2 nr axSpA: non-radiographic axial spondyloarthritisNumbers may not add due to rounding CER: constant exchange rates

Label extension to include WOCBA (EU)• Psoriasis: potential approval (U.S. & EU)• Nr axial spondyloarthritis²:

Phase 3 results (U.S.)• Psoriasis / psoriatic arthritis:

Phase 3 results (Japan)

• Net sales to reach≥ € 1.5 billion

• Loss of exclusivity (U.S. & EU)

• Loss of exclusivity(Japan)

2018 2020 2024 2026

For patients living with• Rheumatoid arthritis• Psoriatic arthritis• Ankylosing spondylitis /

axial spondyloarthritis• Crohn’s disease

Net sales1

€ million FY 2017 FY 2016 Act CER

U.S. 918 846 8% 11%

Europe 370 339 9% 10%

International markets 136 118 15% 18%

Total Cimzia® 1 424 1 304 9% 11%

2017 FY resultsCimzia® in-market performance 2017 38

1 In-market growth is calculated for MAT period ; US : MAT Nov 2017 vs MAT Nov 2016; Europe & Japan : MAT Dec 2017 vs MAT Dec 20162 Market share is calculated for R3M period

6.2%

5.0%

5.5%

6.0%

6.5%

Nov-16 Feb-17 May-17 Aug-17 Nov-17

Cimzia® RheumatologyR3M Patient Share 2

0.1%1.6%

5.5%

-5%

-3%

-1%

1%

3%

5%

7%

Anti TNF Biologics Cimzia®

Cimzia® vs. Rheumatology Market Growth 1

U.S.

+5.4%

+0.4%

Source: U.S: IQVIA Source of Business Report November 2017

6.4%8.0%

17.0%

0%

5%

10%

15%

20%


Cimzia® vs. RA Market Growth 1

7.1%

10.0%7.6%

0%

5%

10%

15%


Cimzia® vs. RheumatologyMarket Growth 1

Europe Japan

8.3%

7.0%

7.5%

8.0%

8.5%

9.0%

Dec-16 Mar-17 Jun-17 Sep-17 Dec-17

Cimzia® RheumatologyR3M Patient Share 2 -0.3%

Source: IMS MIDASIn-Market KPI’s are based on Exit Patients

+10.6%

4.3%

2.5%

3.0%

3.5%

4.0%

4.5%


Cimzia® RA R3M Patient Share 2

+0.4%

Source: IMS MIDAS; Cimzia® patients are considered 100% in RAIn-Market KPI’s are based on Exit Patients

+0.5%

2017 FY results 39Vimpat®

1 2016 figures have been restated reflecting IFRS 15 implementation in 2017 2 POS: Partial-onset seizures, also known as focal seizuresNumbers may not add due to rounding 3 PGTCS: Primary Generalized Tonic-Clonic SeizuresCER: constant exchange rate

• PGTCS3: Phase 3 results

• Net sales to reach≥ € 1.2 billion

• Patent expiry (U.S. & EU)

• Loss of exclusivity(Japan)

2019 2020 20242022

For patients living with• Epilepsy – POS2

• Adults, adolescents and children from 4 years of age (EU & U.S.)

• Adults (Japan)

Net sales1

€ million FY 2017 FY 2016 Act CER

U.S. 746 629 19% 21%

Europe 177 152 17% 17%


Total Vimpat® 976 822 19% 21%

2018

POS2: pediatric filing (Japan)

2017 FY results

3.4%

2.5%

2.7%

2.9%

3.1%

3.3%

3.5%


Vimpat® – R3M TDx Share

4.2%

3.5%

3.7%

3.9%

4.1%

4.3%

4.5%


Vimpat® – R3M TRx Share

0.7%

8.9%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TRx)

5.5%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TDx)

1.6%

16.7%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TDx)

Vimpat® in-market performance 40

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S.

+8.2%

+0.3%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

+15.1%

+0.5%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx

Numbers to be populated when sufficient data is

available

1.26%

0.0%0.2%0.4%0.6%0.8%1.0%1.2%1.4%

Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Oct-17 Dec-17

Vimpat® – R3M TDx Share

Source data JP: IMS MIDAS - In-market KPI’s are based on TDx

2017 FY results 41Keppra®

1 2016 figures have been restated reflecting IFRS 15 implementation in 2017 2 POS: Partial-onset seizures, also known as focal seizuresNumbers may not add due to rounding 3 PGTCS: Primary Generalized Tonic-Clonic SeizuresCER: constant exchange rate

• Patent expiry(Japan)

2020


• Epilepsy – PGTCS3

• Epilepsy myoclonic seizures

Net sales1

€ million FY 2017 FY 2016* Act CER

U.S. 232 216 7% 9%

Europe 235 237 -1% -1%


Total Keppra® 778 720 8% 11%

2017 FY results

12.4%

10.0%

12.0%

14.0%

16.0%


Keppra® – R3M TDx Share

5.5%

31.6%

0%

10%

20%

30%

40%

50%

AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

1.6%

2.0%

0.0%

1.0%

2.0%

3.0%

4.0%

5.0%

AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

0.8%0.0%

0.5%

1.0%

1.5%

2.0%


Keppra® – R3M TRx Share

0.7%

-13.0%-15.0%

-10.0%

-5.0%

0.0%

5.0%

AED Market Keppra®

Keppra® vs. AED Market Growth (TRx)

15.6%

10.0%

12.0%

14.0%

16.0%


Keppra® – R3M TDx Share

Keppra® in-market performance 42

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage. For U.S., Keppra® includes Keppra® XR. For EU, Keppra® does not include UCB levetiracetam.

U.S.

-13.7%

-0.1%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-market KPI’s are based on TRx

+0.4%

+0.02%

Source data EU: IMS MIDAS - In-market KPI’s are based on TDx

+26.1%


+2.5%

2017 FY results 43Briviact®

1 2016 figures have been restated reflecting IFRS 15 implementation in 2017 2 POS: Partial-onset seizures, also known as focal seizuresNumbers may not add due to rounding CER: constant exchange rate

• Epilepsy POS2

Phase 3 results (Japan)

2020


Net sales1


• Net sales to reach≥ € 600 million


U.S. 63 11 > 100% > 100%Europe 22 7 > 100% > 100%International markets 1 0 N/A N/ATotal Briviact® 87 18 >100% >100%

2026

2017 FY resultsBriviact® in-market performance 44

A new therapeutic option in the AED market

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S. Europe

Source data U.S.: U.S. IMS NPAIn-Market KPIs are based on TRx

Source data EU: IMS MIDASIn-Market KPI’s are based on TDx

0.25%

0.00%

0.10%

0.20%

0.30%

0.40%

0.50%

0.60%

0.70%


Briviact® – R3M TRx Share

0.58%

0.00%

0.10%

0.20%

0.30%

0.40%

0.50%

0.60%

0.70%


Briviact® – R3M TDx Share

2017 FY results 45Neupro®

1 2016 figures have been restated reflecting IFRS 15 implementation in 2017 * Numbers may not add due to rounding

CER: constant exchange rate

• Net sales to reach≥ € 400 million

2020

For patients living with• Parkinson’s disease• Restless legs syndrome

Net sales1

• Patent expiry (Japan)

2024


U.S. 96 85 13% 15%

Europe 168 161 4% 5%

International markets 50 52 -4% 0%

Total Neupro® 314 298 5% 7%


2021

2017 FY results

29.6%

25%

26%

27%

28%

29%

30%


Neupro® PD – R3M TDx Share

6.7%

6.0%

6.5%

7.0%

7.5%

8.0%

8.5%


Neupro® PD – R3M TRx Share

0.9% 0.8%

5.2%

-4.0%

-2.0%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%

PD Market PD KeyCompetitors

Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

17.9%

16.0%

16.5%

17.0%

17.5%

18.0%

18.5%


Neupro® PD – R3M TDx Share

0.0%-2.7%

9.8%

-4%-2%0%2%4%6%8%

10%


Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

-1.0% -1.0% -1.8%-4.0%

-2.0%

0.0%

2.0%

4.0%

6.0%

8.0%

10.0%


Neupro®

Neupro® PD vs. PD (KC) Market Growth (TRx)

Neupro® in-market performance 46

PD market: All molecules in ATC3= N4A. In the Europe and Japan, the TDx of all these molecules are factored for PD usage. In the U.S., only the TRx of Rotigotine, Pramipexole and Ropinirole are factored for PD usagePD Key Competitors (KC) market: The 8 DA’s (Dopamine Antagonists): Bromocriptine, Cabergoline, Lisuride, Pergolide, Rotigotine, Pramipexole, Piribedil, Ropinirole. In the US, only Rotigotine, Pramipexole and Ropinirole are factored for PD usage, hence the PD market and PD KC market are the same.

U.S.

-0.8%

+0.0%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-market KPI’s are based on TRx

+4.4%

+0.8%

Source data EU: IMS MIDAS - In-market KPI’s are based on TDx

+12.5%

+3.3%


2017 FY results

Translating scientific hypotheses into clinical development47

1 APDS - Activated PI3K Delta Syndrome2 MG – myasthenia gravis

Evenity™ (romosozumab)osteoporosis

bimekizumab (IL17A/F)psoriasispsoriatic arthritisankylosing spondylitis

Phase 3 program results Q4 2019

Phase 3 to start H2 2018Phase 3 to start H2 2018

dapirolizumab pegol (CD40L antibody)systemic lupus erythematosus Phase 2b results: Q4 2018 (Partner: Biogen)

padsevonil (PPSI)highly drug-resistant epilepsy Phase 2b results H1 2020

seletalisib (PI3K δ inhibitor)Sjögren’s syndrome + APDS1 (Phase 1b) Phase 2a results: Q3 2018

rozanolixizumab (FcRn)immune thrombocytopenia + MG2 Phase 2a results: H2 2018

UCB4144 / VR942 - asthma (Partner: Vectura)

UCB6673 ; UCB7858 ; UCB0159

UCB3491 ; UCB0599 neurology

immunology

FilingPhase 3Phase 2Phase 1

bone

Evenity™ is the trade name of romosozumab which has been provisionally approved bythe U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).

2017 FY resultsEvenity™ (romosozumab) 48

An innovative investigational bone-forming therapy

STRUCTURE, FRAME, BRIDGE and ARCH• Phase 3 studies completed

Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures

Dual effect on bone - increases bone formation and decreases bone resorption

Under regulatory review in the U.S., Canada, Japan, Australia, Braziland EU, Switzerland

• Complete Response Letter in the U.S. (July 2017)

Manorama, living with osteoporosis

*The trademark EVENITY™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).EVENITY™ (romosozumab) is developed in partnership with Amgen globally.

2017 FY results

Vimpat®

epilepsy POS –pediatric

CHMP opinion (EU)

UCB0159immunologyPhase 1 start

rozanolixizumabmyasthenia gravis

Phase 2a start

Vimpat®

epilepsy POS –ped. adj. therapy

Filing (U.S.)

bimekizumab add on to Cimzia®

rheumatoid arthritisPhase 2a results

R&D milestones in 2017

POS: Partial-Onset Seizures, also known as focal seizures CRL: complete response letterCHMP: Committee for Medicinal Products for Human Use ITP: immune thrombocytopenia

49

neurology

immunologybone

romosozumabosteoporosis in

post-menopausal women (ARCH)Phase 3 results

padsevonilhighly drug

resistant epilepsyPhase 2a results

Vimpat®

epilepsy POS –ped. adj. therapy Phase 3 results

Cimzia®

psoriasisPhase 3 results

bimekizumab psoriasis

Phase 2b results

Cimzia®

psoriasis / psoriatic arthritis - Phase 3

start (Japan)

Briviact®

epilepsy POS –monotherapyFiling (U.S.)

Briviact®

epilepsy POS –ped. adj. therapy

Filing (EU & U.S.)

Cimzia®

juvenile idiopathic arthritis

CRL (U.S.)


post-menopausal women

CRL (U.S.)

Cimzia®

psoriasisFiling (EU)

Vimpat®

epilepsy POS –monotherapy

Approval (Japan)

Briviact®

epilepsy POS –adj. therapy

Phase 3 start(Japan)

Vimpat®


Approval (EU)

Briviact®

epilepsy POS –monotherapy

Approval (U.S.)

Cimzia®

psoriasisFiling (U.S.)


Phase 3 start

Vimpat®

epilepsy POS –ped. adj. therapy Approval (U.S.)

bimekizumab psoriatic arthritisPhase 2b results

bimekizumab ankylosing spondylitis

Phase 2b results

rozanolixizumabITP

Phase 2a results

Cimzia®

CRIB & CRADLE Filing (EU)

Cimzia®

CRIB & CRADLE filing (U.S.)

2017 FY results

2018 2019 2020

Upcoming R&D milestones

nr axSpA: non-radiographic axial spondyloarthritisSLE: Systemic Lupus ErythematosusPGTCS: Primary generalized tonic-clonic seizures

50

Cimzia®

nr axSpA (U.S.)Phase 3 results

dapirolizumab pegolSLE

Phase 2b results

Vimpat®

epilepsy PGTCS –adj. therapy

Phase 3 results

Cimzia®

psoriasis / psoriatic arthritis - Phase 3

results (Japan)

rozanolixizumabmyasthenia gravisPhase 2a results

padsevonilhigh drug resistant

epilepsyPhase 2b start

Cimzia®

psoriasisregulatory feedback

(U.S. / EU)


Phase 3 results

padsevonilhigh drug resistant

epilepsyPhase 2b results

seletalisibSjögren’s syndrome

Phase 2a results

Cimzia®

CRIB & CRADLE label extension

(EU)


post-menopausal women

Filing (EU)

bimekizumab psoriatic athritisPhase 3 start

bimekizumab ankylosing spondylitis

Phase 3 start

Vimpat®


Filing (Japan)

neurology

immunologybone

2017 FY resultsOne UCB today: A global player 51

Presence in 38 countries complemented by a robust network of partners

December 2017

7 478employees

globally

2017 FY results 52Stable shareholder base with free-float of 62%Weighted average shares outstanding in 2017: 188 million

“Free float” investors by region

Source: Notifications and UCB underlying ownership analysis, Dec. 2017

2017 FY results 53

ן Antje Witte, Vice President Investor Relations• Phone: +32 2 559 9414• E-mail: [email protected]

ן Isabelle Ghellynck, Director Investor Relations• Phone: +32 2 559 9588• E-mail: [email protected]

ן Nathalie Deldime, Investor Relations Manager• Phone: +32 2 559 9291• E-mail: [email protected]

ן Check out our new IR App – stay tuned wherever you go

Your UCB Investor Relations team

Documents

UCB Inspired by patients. Driven by science.€¦ · UCB Inspired by patients. Driven by science. 2017 full year financial report Brussels, 22 February 2018. Disclaimer and safe harbor